I too tried to follow the progress of Apeiron's APN01 which started to get news coverage at the end of February due to a University of British Columbia press re

I too tried to follow the progress of Apeiron's APN01 which started to get news coverage at the end of February due to a University of British Columbia press release [1]. This pre-existing therapeutic was created out of SARS-CoV-1 research and I expected a SARS-CoV-2 trial to be accelerated. It never happened. There is a story to be told here. Either a missed opportunity, incompetence, or a complete misunderstanding on my part of what a promising COVID-19 therapeutic looks like. [1] https://www.med.ubc.ca/news/pilot-clinical-trial-in-china-to-test-ubc-researchers-findings-as-a-targeted-therapy-for-covid-19/ https://www.med.ubc.ca/news/pilot-clinical-trial-in-china-to...